Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Equity Average (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Equity Average for 6 consecutive years, with $288.7 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 36.8% to $288.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $288.7 million through Dec 2025, down 36.8% year-over-year, with the annual reading at $315.5 million for FY2025, 39.19% down from the prior year.
  • Equity Average hit $288.7 million in Q4 2025 for Lyell Immunopharma, down from $314.0 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $1.0 billion in Q3 2021 to a low of -$313.3 million in Q1 2021.
  • Historically, Equity Average has averaged $595.3 million across 5 years, with a median of $652.7 million in 2023.
  • Biggest five-year swings in Equity Average: soared 496.33% in 2021 and later crashed 45.67% in 2025.
  • Year by year, Equity Average stood at $958.1 million in 2021, then dropped by 13.72% to $826.6 million in 2022, then fell by 18.19% to $676.3 million in 2023, then tumbled by 32.46% to $456.8 million in 2024, then plummeted by 36.8% to $288.7 million in 2025.
  • Business Quant data shows Equity Average for LYEL at $288.7 million in Q4 2025, $314.0 million in Q3 2025, and $317.7 million in Q2 2025.